Positron Emission Tomography in Detecting Testicle Cancer (NCT00045045) | Clinical Trial Compass
CompletedNot Applicable
Positron Emission Tomography in Detecting Testicle Cancer
United KingdomStarted 2002-05
Plain-language summary
RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to detect the extent of cancer and allow doctors to plan more effective treatment for patients who have testicle cancer.
PURPOSE: Diagnostic trial to study the effectiveness of positron emission tomography using fludeoxyglucose F 18 in predicting relapse in patients who have stage I germ cell tumor of the testicle.
Who can participate
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed non-seminomatous or mixed seminoma/non-seminomatous germ cell tumor of the testis with evidence of vascular (lymphatic or venous) invasion in primary specimen
* Clinical stage I on the basis of clinical examination, chest x-ray, and CT scan of the chest, abdomen, and pelvis
* Negative post-orchidectomy tumor markers (alpha-fetoprotein and beta human chorionic gonadotropin)
* High-risk disease
PATIENT CHARACTERISTICS:
Age
* Any age
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Other
* No evidence of active inflammatory or infective diseases
* No other disease or prior malignancy that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* Not specified
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* See Disease Characteristics
* No more than 8 weeks since prior orchidectomy
Other
* No prior positron emission tomography scans
Trial details
NCT IDNCT00045045
SponsorInstitute of Cancer Research, United Kingdom